In prostate cancer cells, KAT8 is able to catalyze the level of H4K16 acetylation modification in the promoter region of nuclear factor-κ B (NF-κB) to enhance its transcriptional activity, whereas the activation of NF-κB promotes the deacetylation of KAT8 by SIRT1 to downregulate the level of H4K16ac [43]. This evidence concerns the gene KAT8 and prostate carcinoma.